Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(21)00263-2
- PMID
- 34019801
- PMCID
- PMC8131060
- OpenAlex
- W3162255312
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The paper is relevant to vaccine development policy, trial continuity, and ethical conduct during rollout. It focuses on equitable access and respectful treatment of participants and host communities rather than on disease surveillance or outcome estimation.
Structured evidence summary
Research question
How will widespread COVID-19 vaccine rollout affect ongoing and planned phase 2 and 3 vaccine trials, and what trial approaches may be appropriate in different access settings?
Study design
A peer-reviewed journal article that presents a narrative, perspective-style discussion of trial challenges, ethics, and future trial options rather than original participant-level research.
Population and setting
COVID-19 vaccine candidates and their phase 2/3 randomized placebo-controlled trials, with emphasis on high-income countries and on low- and middle-income or resource-poor settings where vaccine access differs.
Main findings
The abstract says vaccine deployment will substantially affect ongoing placebo-controlled trials, especially where broad adult or older-age coverage is expected. It also states that sponsors should consider continuing studies in places with limited vaccine access, and that non-inferiority immunogenicity trials and crossover placebo-controlled designs may be used.
Public-health relevance
The paper is relevant to vaccine development policy, trial continuity, and ethical conduct during rollout. It focuses on equitable access and respectful treatment of participants and host communities rather than on disease surveillance or outcome estimation.
Important limitations
No empirical results are presented in the abstract, and the piece mainly offers recommendations and ethical considerations. This summary is limited to the supplied single-article abstract and metadata, so the full paper is needed for decision-grade interpretation.
GIDS interpretation
This article is straightforward to discover as a 2021 Lancet Infectious Diseases discussion of COVID-19 vaccine trial design and ethics. It should be treated as contextual literature, not as evidence of a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.